Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -60.64% | -194.58% | -68.46% | 23.48% | -104.18% |
| Total Depreciation and Amortization | 46.15% | 46.15% | 7.14% | 650.00% | 766.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 235.42% | 196.12% | 100.90% | -84.87% | 243.39% |
| Change in Net Operating Assets | -163.76% | 255.33% | -507.44% | -18.89% | 154.95% |
| Cash from Operations | -98.28% | -92.68% | -273.72% | -63.54% | 4.60% |
| Capital Expenditure | -- | -- | 90.83% | 94.67% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 90.83% | 94.67% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.85% | 235.77% | -- | 396,970.24% | 3,992.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -81.61% | 235.77% | -100.50% | 737.39% | -96.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.80% | -92.09% | -116.67% | 984.54% | -325.13% |